Project Grant HT94252510520
Award Date
9/15/25
Completion Date
9/14/28
Dollars Obligated
$992K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The federal Project Grant award of $999,806.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to study innate lymphoid cells as new targets to reduce vascularized composite tissue transplant rejection. The award, which runs from September 30, 2024 to September 29, 2027, will enable MGH to conduct innovative biomedical research,...
The Massachusetts General Hospital was awarded a $999,792 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research into regulatory T-cell expansion and immune modulation in vascularized composite tissue transplants from September 15, 2021 through September 14, 2024. The Military Medical Research and Development program supports biomedical research that transforms military and public...
The Department of the Army Medical Command awarded a $1,248,949 Project Grant to Massachusetts General Hospital through the Military Medical Research and Development program. The grant will fund research into stable mixed chimerism and tolerance of vascularized composite allografts via BCL-2 inhibition from September 30, 2022 to August 31, 2025. The Military Medical Research and Development program supports innovative biomedical research with the goals of improving military and public health...
The Department of the Army Medical Command has awarded a $1,644,309 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The award, which runs from February 1, 2025, to January 31, 2028, will fund research aimed at "FUNCTIONAL MOLECULAR NETWORKS MODIFYING HIF2A ACTIVITY IN VHL TUMORS." As a renowned academic medical center and major recipient of federal...
The General Hospital Corporation, doing business as Massachusetts General Hospital, was awarded a $302,801 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from September 1, 2022 to August 31, 2025 to advance a tissue oxygenation measurement device and evaluate galectin-3 as novel noninvasive prognostic biomarkers for monitoring vascularized composite...
The Department of the Army Medical Command awarded a $204,480 Project Grant to the Massachusetts General Hospital through the Military Medical Research and Development program. The grant will fund research into stable mixed chimerism and tolerance of vascularized composite allografts via BCL-2 inhibition from September 30, 2022 through August 31, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of improving...
This Project Grant award, valued at $1,618,114.00 and effective from April 1, 2025 to March 31, 2028, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports research conducted by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to define the role of anti-nephrin antibodies in the recurrence of focal segmental glomerulosclerosis post transplantation. This...
The Department of the Army Medical Command, through the Military Medical Research and Development (CFDA 12.420) federal grant program, awarded a $1,498,368 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a performance period from August 1, 2024 to July 31, 2027. The grant supports research to elucidate the molecular mechanisms of tumor-immune dynamics and evolution in response to radiation, in order to optimize treatment of high-...
The Department of the Army Medical Command awarded a $1,234,505.00 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "COTARGETING THE TUMOR MICROENVIRONMENT TO REVOLUTIONIZE ANTIBODY-DRUG CONJUGATE THERAPY FOR REFRACTORY BREAST CANCERS". The award, which runs from March 1, 2025 to February 29, 2028, will support advanced biomedical...
The Department of the Army Medical Command awarded a $888,632 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on "Deciphering the Role of Maternal Autoantibodies in the Induction of Offspring Behavioral Abnormalities Following Maternal TLR7 Activation." The award period is from April 1, 2025 to March 31, 2027. MGH, a renowned nonprofit...